Wordt geladen...

Bayesian designs to account for patient heterogeneity in phase II clinical trials

PURPOSE OF REVIEW: Between-patient heterogeneity is very common in clinical trials. This complicates treatment evaluation, due to known prognostic subgroup effects or potential treatment-subgroup interactions. We review two Bayesian phase II clinical trial designs that account explicitly for patient...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Curr Opin Oncol
Hoofdauteurs: Thall, Peter F., Wathen, J. Kyle
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2008
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5555403/
https://ncbi.nlm.nih.gov/pubmed/18525336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0b013e328302163c
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!